WIL Research Laboratories has acquired Midwest BioResearch (MBR). The two companies will integrate their service offerings and share best practices and marketing.

Midwest BioResearch has expertise in immunoanalytical and bioassay techniques and small molecule bioanalysis, supporting clinical and nonclinical research, and expertise in genetic toxicology, adding to WIL Research’s contract research service offerings including chronic, neuro-, inhalation, and intravenous toxicology, developmental and reproductive toxicology, safety pharmacology, bioanalytical chemistry and metabolism.

Michael Schlosser, Ph.D., DABT, MBR’s president and founder, will continue to lead the existing Skokie, IL site, reporting to Christopher P. Chengelis, Ph.D., DABT, WIL’s vice president and chief scientific officer.

“Midwest BioResearch rounds out our service offerings, particularly in the areas of genetic toxicity and biotech and clinical support capabilities,” said Dr. Chengelis. “We also benefit from a world-class staff with significant pharmaceutical and biotechnology industry experience and the addition of a program services consulting group.”

Sal Guccione, chief executive officer at WIL Research Holding Co., stated, “This transaction greatly enhances our capabilities to serve our clients in small and large molecule drug development. We are delighted to welcome this experienced team to the WIL family of research companies.”